Athenex dis­clos­es pa­tient death, clin­i­cal hold on CAR-NKT tri­al as it seeks strate­gic al­ter­na­tives

A neu­rob­las­toma pa­tient has died af­ter re­ceiv­ing Athenex’s nat­ur­al killer cell ther­a­py, trig­ger­ing a clin­i­cal hold, the com­pa­ny re­vealed.

Bay­lor Col­lege of Med­i­cine, which is run­ning the tri­al, has iden­ti­fied some of the con­di­tions lead­ing up to the pa­tient’s death and is “de­vis­ing a safe­ty risk mit­i­ga­tion plan” to re­open the tri­al, ac­cord­ing to Athenex. It did not re­turn re­quests for com­ment on when the pa­tient’s death oc­curred.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN